Cargando…
Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
Patients with classical Hodgkin lymphoma (cHL) have an impaired cellular immune response as indicated by an anergic reaction against standard recall antigens and a diminished rejection reaction of allogeneic skin transplant. This clinical observation can be linked to the histopathological feature of...
Autores principales: | Renner, Christoph, Stenner, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994413/ https://www.ncbi.nlm.nih.gov/pubmed/29915720 http://dx.doi.org/10.3389/fonc.2018.00193 |
Ejemplares similares
-
Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
por: Stenner, Frank, et al.
Publicado: (2018) -
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021) -
The role of transplantation in Hodgkin lymphoma
por: Maranzano, Michael, et al.
Publicado: (2023) -
Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023) -
Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)